GLP-1 & Metabolic
Vive GLP(S)
Formula
- Size
- 5mg
Specifications
Vive GLP(S) Technical Profile
OVERVIEW
What Is Semaglutide Peptide?
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1), originally developed as a research compound to study incretin biology and metabolic signaling pathways. The semaglutide peptide features key structural modifications, including an aminoisobutyric acid (Aib) substitution at position 8 and a C-18 fatty diacid chain attached via a linker at lysine-26, that confer enhanced resistance to dipeptidyl peptidase-4 (DPP-4) degradation and increased albumin binding affinity.
As a semaglutide research peptide, this compound has become one of the most studied GLP-1 receptor agonists in the scientific literature. Its unique pharmacokinetic profile, resulting from the fatty acid acylation strategy, makes it a valuable tool for researchers investigating GLP-1 receptor signaling, glucose homeostasis, and metabolic pathway regulation in laboratory settings. Semaglutide research continues to generate significant interest across multiple areas of preclinical investigation.
- 01
GLP-1 Receptor Agonist
Acylated peptide analog of human glucagon-like peptide-1
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
Semaglutide Mechanism of Action in Research
The semaglutide mechanism of action centers on its interaction with the GLP-1 receptor, a G-protein coupled receptor expressed in multiple tissue types. Semaglutide research has elucidated how the structural modifications of this peptide influence its receptor binding kinetics and downstream signaling cascades in laboratory models.
GLP-1 Receptor Binding and cAMP Signaling
Semaglutide binds to the GLP-1 receptor with high affinity, activating the adenylyl cyclase pathway and increasing intracellular cyclic adenosine monophosphate (cAMP) levels. In pancreatic beta cell research models, this cAMP elevation has been shown to potentiate glucose-dependent insulin secretion. The C-18 fatty diacid modification enables non-covalent albumin binding, significantly extending the compound's half-life in research models and making it valuable for studying sustained GLP-1 receptor activation (Lau et al., Journal of Medicinal Chemistry, 2015).
Central Nervous System Pathway Research
Semaglutide GLP-1 research has expanded to include investigations of GLP-1 receptor signaling in the central nervous system. Studies in animal models suggest that semaglutide may cross the blood-brain barrier and interact with GLP-1 receptors in hypothalamic regions involved in appetite regulation and energy homeostasis. Published research has documented effects on neuronal activation patterns in specific brain regions following semaglutide administration in rodent models (Gabery et al., JCI Insight, 2020).
Inflammatory Pathway Modulation
Additional semaglutide research has explored its potential interactions with inflammatory signaling pathways. Preclinical studies indicate that GLP-1 receptor activation by semaglutide may modulate NF-κB signaling and reduce markers of inflammation in various tissue types. These findings have broadened the scope of semaglutide research beyond its originally characterized metabolic pathways. ---
COMPARISON
Semaglutide vs Tirzepatide: Research Peptide Comparison
Semaglutide
Semaglutide and tirzepatide represent two of the most actively studied incretin-based peptides in current research. While semaglutide is a selective GLP-1 receptor agonist, tirzepatide functions as a dual GIP/GLP-1 receptor agonist, creating distinct pharmacological profiles for laboratory investigation.
Tirzepatide
Both compounds are available from VivePeptides at research grade semaglutide 99% purity. The choice between these peptides depends on the specific receptor pathways and research questions under investigation. Researchers studying selective GLP-1 receptor activation often prefer semaglutide, while those investigating dual incretin signaling may select tirzepatide.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 receptor (selective) | GIP and GLP-1 receptors (dual agonist) |
| CAS Number | 910463-68-2 | 2023788-19-2 |
| Molecular Weight | 4113.58 Da | 4813.45 Da |
| Amino Acids | 31 (modified GLP-1 analog) | 39 (GIP-based backbone) |
| Acylation | C-18 fatty diacid | C-20 fatty diacid |
| DPP-4 Resistance | Aib8 substitution | Aib2 substitution |
| Research Classification | GLP-1 receptor agonist | Dual incretin receptor agonist |
| Primary Research Focus | GLP-1 signaling, metabolic research | Dual incretin signaling, metabolic research |
RESEARCH STUDIES
Semaglutide Research Applications & Published Studies
The semaglutide research literature encompasses hundreds of published studies across metabolic, cardiovascular, and neurological research domains. The following highlights represent key areas of investigation using semaglutide peptide in preclinical and research settings.
Metabolic Pathway Research
Semaglutide has been extensively studied in models of glucose homeostasis and metabolic signaling. Research by Knudsen et al. (Journal of Medicinal Chemistry, 2000) and subsequent studies have characterized the structure-activity relationships of GLP-1 analogs, establishing the foundation for understanding how semaglutide's structural modifications influence receptor pharmacology. Studies in rodent models have documented semaglutide's effects on insulin secretion dynamics, glucagon suppression, and gastric motility in research settings.
Cardiovascular Research Models
Published semaglutide research includes investigations of GLP-1 receptor signaling in cardiovascular tissue models. Preclinical studies have examined semaglutide's effects on endothelial function, lipid metabolism, and vascular inflammation markers in animal models. Rakipovski et al. (JACC, 2018) published findings on semaglutide's effects in atherosclerosis models, expanding the scope of cardiovascular-focused GLP-1 research.
Neuroscience Applications
Emerging semaglutide research has explored GLP-1 receptor agonism in neuroscience models. Published studies have examined semaglutide in models of neuroinflammation and neurodegeneration, with researchers investigating its ability to engage central GLP-1 receptors. This area of semaglutide research represents a rapidly growing field of preclinical investigation.
QUALITY ASSURANCE
Quality & Testing Standards
VivePeptides ensures every batch of semaglutide research peptide meets the highest analytical standards for purity, identity, and consistency.
HPLC & Mass Spectrometry
Every semaglutide batch undergoes HPLC and mass spectrometry analysis to verify peptide identity, purity, and correct molecular weight.
Third-Party Verified
All semaglutide is independently tested at third-party USA-based analytical laboratories. Results are available for each lot number.
≥99% Purity Standard
VivePeptides semaglutide consistently meets or exceeds ≥99% purity, ensuring research-grade quality for all laboratory applications.
FAQ
Frequently Asked Questions About Semaglutide
What is semaglutide used for in research?
What purity is VivePeptides semaglutide?
How should semaglutide be stored?
What makes semaglutide different from native GLP-1?
Is VivePeptides semaglutide third-party tested?
Add To Research Cart
Vive GLP(S)
99%+ purity · USA lab tested · secure shipping
